- Home
- TLPH vs BRNS Comparison
TLPH vs BRNS Comparison
Compare TLPH & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- BRNS
- Stock Information
- Founded
- TLPH 2005
- BRNS 2016
- Country
- TLPH United States
- BRNS United Kingdom
- Employees
- TLPH N/A
- BRNS N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- BRNS Health Care
- Exchange
- TLPH Nasdaq
- BRNS Nasdaq
- Market Cap
- TLPH 64.7M
- BRNS 55.9M
- IPO Year
- TLPH 2011
- BRNS 2021
- Fundamental
- Price
- TLPH $1.34
- BRNS $0.75
- Analyst Decision
- TLPH Strong Buy
- BRNS Strong Buy
- Analyst Count
- TLPH 1
- BRNS 1
- Target Price
- TLPH $6.00
- BRNS $4.00
- AVG Volume (30 Days)
- TLPH 318.3K
- BRNS 134.6K
- Earning Date
- TLPH 11-12-2025
- BRNS 11-07-2025
- Dividend Yield
- TLPH N/A
- BRNS N/A
- EPS Growth
- TLPH N/A
- BRNS N/A
- EPS
- TLPH N/A
- BRNS N/A
- Revenue
- TLPH $28,000.00
- BRNS N/A
- Revenue This Year
- TLPH N/A
- BRNS N/A
- Revenue Next Year
- TLPH $14,533.26
- BRNS N/A
- P/E Ratio
- TLPH N/A
- BRNS N/A
- Revenue Growth
- TLPH N/A
- BRNS 1766.46
- 52 Week Low
- TLPH $0.38
- BRNS $0.64
- 52 Week High
- TLPH $1.45
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- TLPH 57.82
- BRNS 24.92
- Support Level
- TLPH $1.01
- BRNS $0.75
- Resistance Level
- TLPH $1.35
- BRNS $0.81
- Average True Range (ATR)
- TLPH 0.11
- BRNS 0.11
- MACD
- TLPH -0.01
- BRNS -0.04
- Stochastic Oscillator
- TLPH 80.49
- BRNS 0.06
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.